BR112015011148A8 - composto, composição farmacêutica, e combinação - Google Patents

composto, composição farmacêutica, e combinação

Info

Publication number
BR112015011148A8
BR112015011148A8 BR112015011148A BR112015011148A BR112015011148A8 BR 112015011148 A8 BR112015011148 A8 BR 112015011148A8 BR 112015011148 A BR112015011148 A BR 112015011148A BR 112015011148 A BR112015011148 A BR 112015011148A BR 112015011148 A8 BR112015011148 A8 BR 112015011148A8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
combination
pi3k
delta
Prior art date
Application number
BR112015011148A
Other languages
English (en)
Other versions
BR112015011148A2 (pt
Inventor
Abe Achab Abdelghani
Mu Changwei
Xavier Fradera Lljnas Francesc
Zhou Hua
D Katz Jason
L Methot Joey
Chiu Fong King
P Christopher Matthew
Mcgowan Meredeth
D Altman Michael
John Anthony Neville
Zhang Rong
Zhang Sixing
Kattar Solomon
Guzi Timothy
Leng Xiansheng
Deng Yongqi
Garcia Yudith
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112015011148A2 publication Critical patent/BR112015011148A2/pt
Publication of BR112015011148A8 publication Critical patent/BR112015011148A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C07D473/38—Sulfur atom attached in position 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1 / 1 resumo “composto, composiã‡ãƒo farmacãšutica, e, mã‰todos para tratar uma doenã‡a e uma condiã‡ãƒo” a presente invenã§ã£o fornece o composto da fã³rmula i, que sã£o inibidores de pi3k-delta, e como tal sã£o ãºteis para o tratamento de doenã§as mediadas por pi3k-delta tal como inflamaã§ã£o, asma, copd e cã¢ncer.
BR112015011148A 2012-11-16 2013-11-15 composto, composição farmacêutica, e combinação BR112015011148A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261727416P 2012-11-16 2012-11-16
PCT/CN2013/001394 WO2014075392A1 (en) 2012-11-16 2013-11-15 Purine inhibitors of human phosphatidylinositol 3-kinase delta

Publications (2)

Publication Number Publication Date
BR112015011148A2 BR112015011148A2 (pt) 2017-07-11
BR112015011148A8 true BR112015011148A8 (pt) 2019-10-01

Family

ID=50730541

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015011148A BR112015011148A8 (pt) 2012-11-16 2013-11-15 composto, composição farmacêutica, e combinação

Country Status (11)

Country Link
US (1) US9730940B2 (pt)
EP (1) EP2920171B1 (pt)
JP (1) JP6297582B2 (pt)
KR (1) KR20150082613A (pt)
CN (1) CN104918939B (pt)
AU (1) AU2013347538B2 (pt)
BR (1) BR112015011148A8 (pt)
CA (1) CA2891009A1 (pt)
MX (1) MX2015006191A (pt)
RU (1) RU2658006C2 (pt)
WO (1) WO2014075392A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
MD4649C1 (ro) 2013-12-05 2020-04-30 Pfizer Inc. Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
AU2015226679B2 (en) 2014-03-06 2017-05-25 Shanghai Haiyan Pharmaceutical Technology Co. Ltd Piperidine derivatives as orexin receptor antagonist
CN104030998B (zh) * 2014-06-05 2015-11-18 华东师范大学 4-多氟烷基-4，5-二取代异噁唑衍生物及其制备方法
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016057924A1 (en) * 2014-10-10 2016-04-14 Genentech, Inc. Pyrrolidine amide compounds as histone demethylase inhibitors
EP3411375B1 (en) 2016-02-04 2020-08-05 Chiesi Farmaceutici S.p.A. Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
WO2017166104A1 (en) * 2016-03-30 2017-10-05 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
DK3512857T3 (da) * 2016-09-14 2021-05-10 Janssen Pharmaceutica Nv Spiro-bicykliske inhibitorer af menin-mll-interaktion
US10494370B2 (en) * 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
CN113620976B (zh) * 2020-05-09 2023-09-26 中国医学科学院药物研究所 噻唑并嘧啶类化合物及其制备方法、用途和药物组合物
WO2022209916A1 (ja) * 2021-03-29 2022-10-06 株式会社カネカ （２－メチルピリミジン－５－イル）ボロン酸誘導体の製造方法
CN113072480B (zh) * 2021-04-13 2022-09-30 常州佳德医药科技有限公司 一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用
WO2024083237A1 (en) * 2022-10-20 2024-04-25 Impact Therapeutics (Shanghai) , Inc Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
ES2536972T5 (es) * 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
SE0300456D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
KR20060021881A (ko) * 2003-06-12 2006-03-08 노보 노르디스크 에이/에스 호르몬 민감성 리파제의 억제제로서의 사용을 위한 치환된피페리딘 카르바메이트
EP1751159A2 (en) 2004-04-28 2007-02-14 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
JP5274460B2 (ja) * 2006-08-08 2013-08-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素のインヒビターとして有用なヘテロアリール化合物
US8008307B2 (en) * 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
US8513221B2 (en) 2008-07-07 2013-08-20 Xcovery Holding, LLC PI3K isoform selective inhibitors
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
WO2012003264A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
TWI617560B (zh) * 2010-09-14 2018-03-11 伊塞利克斯公司 PI3Kδ 抑制劑以及其應用和生產方法
EP2616442B8 (en) 2010-09-14 2018-10-17 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
CN102838600A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂

Also Published As

Publication number Publication date
CN104918939A (zh) 2015-09-16
KR20150082613A (ko) 2015-07-15
EP2920171B1 (en) 2018-08-29
CN104918939B (zh) 2018-08-28
CA2891009A1 (en) 2014-05-22
EP2920171A4 (en) 2016-06-22
AU2013347538B2 (en) 2017-04-27
MX2015006191A (es) 2015-08-10
RU2015122895A (ru) 2017-01-10
US20150353552A1 (en) 2015-12-10
JP2015537010A (ja) 2015-12-24
RU2658006C2 (ru) 2018-06-19
BR112015011148A2 (pt) 2017-07-11
EP2920171A1 (en) 2015-09-23
WO2014075392A1 (en) 2014-05-22
AU2013347538A1 (en) 2015-05-07
JP6297582B2 (ja) 2018-03-20
US9730940B2 (en) 2017-08-15

Similar Documents

Publication Publication Date Title
BR112015011148A8 (pt) composto, composição farmacêutica, e combinação
BR112015011147A2 (pt) composto, composição farmacêutica, e, métodos para tratamento de uma doença e de uma condição
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
BR112015024050A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2015001771A1 (es) Inhibidores de histona desmetilasa
BR112017019453A2 (pt) compostos e composições de alfa-cinamida como inibidores de hdac8
CR20120202A (es) Métodos y composiciones para tratar cáncer
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
CU20110168A7 (es) Derivados de benzofuranilo
IN2014MN02069A (pt)
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
CO6551721A2 (es) Moduladores de cinasa novedosos
IN2014MN00986A (pt)
BR112013025415A2 (pt) métodos para aumentar eficácia de terapia de câncer de folr1
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
BR112015021222A2 (pt) inibidores de ras e usos dos mesmos
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
IN2014MN00988A (pt)
GB201118656D0 (en) New compounds
BR112015023060A2 (pt) entidades químicas
BR112015023858A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112015023891A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
BR112014030416A2 (pt) composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements